Swedish Orphan Biovitrum AB, Athens Office (GR)

https://www.sobi.com

	Start	2017-05-03 established
	Group	Swedish Orphan Biovitrum (Sobi) (Group)
	Industry	DRUGS, ORPHAN

	Region	Athens
	Country	Greece
	City	n. a. Athens
		Address record changed: 2020-12-02

Basic data	Employees	n. a.


		Record changed: 2023-07-10

Picture EBD Group ChinaBio Partnering Forum 2025 Shanghai 650x200px

More documents for Swedish Orphan Biovitrum (Sobi) (Group)

[1] ADC Therapeutics S.A.. (12/21/22). "Press Release: ADC Therapeutics and Sobi Announce European Commission Approval of Zynlonta (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma". Lausanne....
[2] ADC Therapeutics S.A.. (7/8/22). "Press Release: ADC Therapeutics Announces Exclusive License Agreement with Sobi to Develop and Commercialize Zynlonta (loncastuximab tesirine-lpyl) in Europe and Select International Territories". Lausanne....
[3] Swedish Orphan Biovitrum AB. (12/21/20). "Press Release: Sobi Appoints New Head of North America Ahead of Launch Phase"....
[4] AstraZeneca plc. (8/22/19). "Press Release: AstraZeneca Agrees to Buy US FDA Priority Review Voucher from Sobi"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]